Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31270098 | 0.94 | KDM4E (0.64) | KDM4EL3MBTL1ADRB2AOC3 | |
| SCHEMBL31269950 | 0.94 | KDM4E (0.64) | KDM4EL3MBTL1ADRB2AOC3 | |
| SCHEMBL31270029 | 0.89 | KDM4E (0.62) | KDM4ECYP1A2CYP2D6HIF1ABCHE | |
| SCHEMBL31269955 | 0.85 | KDM4E (0.57) | KDM4EL3MBTL1ADRB2AOC3 | |
| SCHEMBL31269749 | 0.85 | KDM4E (0.57) | KDM4EL3MBTL1ADRB2AOC3 | |
| SCHEMBL10877574 | 0.85 | KDM4E (0.88) | KDM4ECYP1A2CYP2D6BCHEL3MBTL1 | |
| SCHEMBL10877567 | 0.85 | KDM4E (0.88) | KDM4ECYP1A2CYP2D6BCHEL3MBTL1 | |
| Hydrochloric Acid SCHEMBL14126826 | 0.85 | KDM4E (0.71) | KDM4EL3MBTL1ADRB2AOC3 | |
| SCHEMBL31269959 | 0.84 | KDM4E (0.71) | KDM4ECYP1A2CYP2D6HIF1ABCHE | |
| SCHEMBL31269709 | 0.82 | KDM4E (0.59) | KDM4EL3MBTL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | claimed |
| WO-2024200768-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | claimed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024200768-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | disclosed |